Clarivate Analytics launched its annual “Drugs to Watch” report, identifying 12 new drugs forecast to achieve annual sales of $1 billion or more (i.e., blockbuster status) by 2022 using the Cortellis database, which includes information gathered from diverse sources including drug pipelines, patents, clinical trials, chemistry, deals, and company announcements. More blockbuster drugs have been predicted to launch in 2018 than in any other year since the Drugs to Watch report began in 2013.
The drugs forecasted to launch in 2018 cover a wide range of therapeutic areas—i.e., type 2 diabetes, endometriosis, childhood epilepsy, hemophilia, HIV, migraine, opioid addiction, and shingles.
2018 is also expected to see the launch of the first FDA-approved cannabidiol-based drug (Epidiolex)—potentially opening up a new market for cannabidiol-based medicines—and the first approved treatment option for men with castration-resistant prostate cancer (Erleada) whose cancer has not yet spread.
“Despite political and regulatory uncertainties in the USA and EU markets, the annual Drugs to Watch report 2018 shows that the pace of pharmaceutical innovation continues to accelerate,” explained Mukhtar Ahmed, president, life sciences at Clarivate Analytics. “2018 is on track to see many new potential game-changing drugs come to market, which will benefit the lives of millions of patients around the world.”
Data for this report were compiled from the Cortellis database, the premier source of life sciences competitive, clinical and regulatory intelligence and analytics which includes data gathered from diverse sources, including annual filings, drug pipelines, clinical trials, patents, chemistry, company announcements, deals, and conferences.
See the full report here.
(Source: Clarivate Analytics)
Filed Under: Drug Discovery